Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

REGN Quantitative Stock Analysis - Benjamin Graham December 30, 2023 — 09:00 am EST Written by John Reese for Validea -> ...

See why I no longer see REGN stock price upside in the near term. Skip to content. ... analysis I set a price target for the stock price of ~$815 - a 10% premium to Regeneron's share price today.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here, it’s free.

The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. ... See our analysis on Regeneron Stock Chances of A Rise for more details.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

At levels of $515, REGN stock is trading at 14x its 2021 estimated adjusted earnings of $36.81, compared to levels of 16x seen in 2018 and over 15x seen as recently as late 2019, implying the ...

Trading at a forward PE ratio of about 11, Regeneron is priced for value. Find out why it offers meaningful growth and significant upside in the years to come.

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...

Regeneron Pharmaceuticals' (REGN-0.25%) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for ...